Impact ledger

Armata Pharmaceuticals Inc. (ARMP): the developments shaping its investment case

Follow the evidence affecting Armata Pharmaceuticals Inc.'s financing assumptions, valuation assumptions. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

Research Armata Pharmaceuticals Inc. · $399/mo

Test assumptions, examine opportunities, and save your research.

Material developments

2026-09-14

Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02

Channel: Regulatory milestone achievement, de-risking of clinical development, enhanced market perception, potential for accelerated approval pathway.

Bullish· 1-3m

2026-09-23

Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War

Channel: Direct non-dilutive funding reduces immediate capital needs and validates program, extending cash runway.

Bullish· 1-3m

Evidence affecting valuation assumptions

Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.

Date	Assumption	Direction	Interpretation
2026-09-23	wacc	Bearish	IG cost of debt is below blended cost of capital; weighting effect lowers WACC.
2026-09-23	interest_expense	Bullish	New IG coupon adds to recurring interest expense.
2026-09-23	net_debt	Bullish	Investment-grade issuance adds gross debt to the balance sheet.
2026-08-15	net_debt	Bullish	Funding of a $25 million term loan increases the company's total debt obligations.
2026-08-15	share_count	Bullish	Issuance of shares via ATM program and stock option exercises increases total shares outstanding.
2026-08-15	wacc	Bullish	Higher cost-of-debt tranche lifts blended WACC.
2026-08-15	interest_expense	Bullish	High-yield coupon materially raises interest burden.
2026-08-15	net_debt	Bullish	Sub-IG debt raise increases leverage and net debt.
2026-08-15	multiple	Bearish	Incremental float typically compresses near-term multiple absent revenue acceleration.
2026-08-15	share_count	Bullish	Primary equity issuance increases diluted share count.
2026-07-20	net_debt	Bearish	Liability-management transactions often reduce gross debt or push maturities out.
2026-07-20	interest_expense	Bearish	Tender/exchange extends maturity profile and typically lowers near-term interest expense.

Event impact log

2 events mapped to ARMP since 2026-09-14. Evidence through 2026-09-23.

Date	Event	Channel	Direction	Horizon	Impact
2026-09-23	Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War	Direct non-dilutive funding reduces immediate capital needs and validates program, extending cash runway.	Bullish	1-3m	0.70
2026-09-14	Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02	Regulatory milestone achievement, de-risking of clinical development, enhanced market perception, potential for accelerated approval pathway.	Bullish	1-3m	0.90

Continue this research

Build your Armata Pharmaceuticals Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.

Research Armata Pharmaceuticals Inc. · $399/mo

This ledger is regenerated from Market Ontology's public event pipeline. View the ARMP entity page →

Armata Pharmaceuticals Inc. (ARMP): the developments shaping its investment case

Material developments

2026-09-14

Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02

Channel: Regulatory milestone achievement, de-risking of clinical development, enhanced market perception, potential for accelerated approval pathway.

Bullish· 1-3m

2026-09-23

Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War

Channel: Direct non-dilutive funding reduces immediate capital needs and validates program, extending cash runway.

Bullish· 1-3m

Evidence affecting valuation assumptions

Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.

Date	Assumption	Direction	Interpretation
2026-09-23	wacc	Bearish	IG cost of debt is below blended cost of capital; weighting effect lowers WACC.
2026-09-23	interest_expense	Bullish	New IG coupon adds to recurring interest expense.
2026-09-23	net_debt	Bullish	Investment-grade issuance adds gross debt to the balance sheet.
2026-08-15	net_debt	Bullish	Funding of a $25 million term loan increases the company's total debt obligations.
2026-08-15	share_count	Bullish	Issuance of shares via ATM program and stock option exercises increases total shares outstanding.
2026-08-15	wacc	Bullish	Higher cost-of-debt tranche lifts blended WACC.
2026-08-15	interest_expense	Bullish	High-yield coupon materially raises interest burden.
2026-08-15	net_debt	Bullish	Sub-IG debt raise increases leverage and net debt.
2026-08-15	multiple	Bearish	Incremental float typically compresses near-term multiple absent revenue acceleration.
2026-08-15	share_count	Bullish	Primary equity issuance increases diluted share count.
2026-07-20	net_debt	Bearish	Liability-management transactions often reduce gross debt or push maturities out.
2026-07-20	interest_expense	Bearish	Tender/exchange extends maturity profile and typically lowers near-term interest expense.

Event impact log

2 events mapped to ARMP since 2026-09-14. Evidence through 2026-09-23.

Date	Event	Channel	Direction	Horizon	Impact
2026-09-23	Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War	Direct non-dilutive funding reduces immediate capital needs and validates program, extending cash runway.	Bullish	1-3m	0.70
2026-09-14	Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02	Regulatory milestone achievement, de-risking of clinical development, enhanced market perception, potential for accelerated approval pathway.	Bullish	1-3m	0.90